Eris Lifesciences transfers 100% stake in 2 arms to Eris Therapeutics for Rs 861.9 crore

Published On 2025-03-07 09:00 GMT   |   Update On 2025-03-07 09:00 GMT

Ahmedabad: Eris Lifesciences has announced that the Company has transferred 100 percent of its holdings in two wholly-owned subsidiaries to Eris Therapeutics Limited, a wholly-owned subsidiary for Rs 861.9 crore. The transfer is a part of Eris Groups’ internal structuring of the holdings.

The two subsidaries are Eris Oaknet Healthcare Private Limited and Aprica Healthcare Limited.

The agreement for the transfer was entered on March 6, 2025 and expected date of completion of sale/disposal is March 31, 2025.

Read also: Eris Lifesciences ropes in Murari Ranganathan as President, Cardiometabolic Business

Established in 2007, Eris is a publicly listed Indian pharma company and is a leading player in the domestic branded formulations market. With an annual branded formulations revenue of INR 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of 2,000+ stockists and 5,00,000+ retail pharmacies.

Eris’ operating revenue and profits have doubled in the last 5 years. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years. For the first 9 months of financial year ending March 2025, the company reported a consolidated revenue of Rs 2,188 crore.

Read also: Submit Source Data of Phase III CT Report: CDSCO Panel Tells Eris Lifesciences on Metoprolol Succinate plus Dapagliflozin FDC

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News